Search
Research
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasiaWe report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adults.
Research
Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccineInfluenza is major cause of paediatric hospitalisation. Influenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008
Research
Human Papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?Cervical cancer mortality has been reduced in Australia because of effective screening programs, but there are still about 800 new cases...
News & Events
Rheumatic heart disease remains a major killer in Oceania regionA new study shows that people living in the Oceania region, including Australia, have the highest risk in the world of dying from rheumatic heart disease.
News & Events
Extra whooping cough shot to protect your bubToddlers will now get an additional whooping cough vaccine to protect them against the potentially deadly disease.
News & Events
Taking on a common respiratory infection in kidsMapping when Respiratory Syncytal Virus (RSV) reaches its seasonal peak will assist how future vaccination programs are carried out.
Research
The impact of obesity on influenza Vaccine immunogenicity - A systematic reviewInfluenza vaccines are important for reducing the burden of influenza, particularly for populations at risk of more severe infections. Obesity is associated with increased influenza severity and therefore individuals with obesity are often specifically recommended for annual influenza vaccination. Obesity is also associated with an altered inflammatory profile, which may influence vaccine responses. This systematic review aimed to evaluate the evidence for any association between obesity and influenza vaccine immunogenicity.
Research
Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody responseSARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.
Research
Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccinesBoth vector and mRNA vaccines were an important part of the response to the COVID-19 pandemic and may be required in future outbreaks and pandemics. The aim of this study was to validate whether immunogenicity differs for adenoviral vectored (AdV) versus mRNA vaccines against SARS-CoV-2, and to investigate how anti-vector immunity and B cell dynamics modulate immunogenicity.
Research
Association between pertussis vaccination in infancy and childhood asthma: A population-based record linkage cohort studyAsthma is among the commonest noncommunicable diseases of childhood and often occurs with other atopic comorbidities. A previous case-control study found evidence that compared to children who received acellular pertussis (aP) vaccines in early infancy, children who received one or more doses of whole-cell pertussis (wP) vaccine had lower risk of developing IgE-mediated food allergy. We hypothesized that wP vaccination in early infancy might protect against atopic asthma in childhood.